Show simple item record

dc.contributor.authorMarques, Cláudia Diniz Lopespt_BR
dc.contributor.authorKakehasi, Adriana Mariapt_BR
dc.contributor.authorGomides, Ana Paula Monteiropt_BR
dc.contributor.authorPaiva, Eduardo dos Santospt_BR
dc.contributor.authorReis Neto, Edgard Torres dospt_BR
dc.contributor.authorPileggi, Gecilmara Cristina Salviatopt_BR
dc.contributor.authorProvenza, José Robertopt_BR
dc.contributor.authorMota, Licia Maria Henrique dapt_BR
dc.contributor.authorXavier, Ricardo Machadopt_BR
dc.contributor.authorFerreira, Gilda Aparecidapt_BR
dc.contributor.authorPinheiro, Marcelo Medeirospt_BR
dc.date.accessioned2022-08-19T04:43:17Zpt_BR
dc.date.issued2020pt_BR
dc.identifier.issn1929-0748pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/247340pt_BR
dc.description.abstractBackground: Patients with immune-mediated rheumatic diseases (IMRD) are at increased risk of infections, including significant morbidity and high mortality. Considering the potential for unfavorable outcomes of SARS-CoV-2 infection in patients with IMRD, several questions were raised regarding the impact of COVID-19 at the start of the pandemic. Objective: This paper presents the protocol of a study that aims to prospectively evaluate patients with IMRD and a confirmed COVID-19 diagnosis (using criteria provided by the Brazilian Ministry of Health). Methods: The study comprised a prospective, observational cohort (patients with IMRD and COVID-19) and a comparison group (patients with only IMRD), with a follow-up time of 6 months to evaluate differences in health outcomes. The primary outcomes will be changes in IMRD disease activity after SARS-CoV-2 infection at 4 time points: (1) at baseline, (2) within 4-6 weeks after infection, (3) at 3 months after the second assessment (±15 days), and (4) at 6 months (±15 days). The secondary outcomes will be the progression rate to moderate or severe forms of COVID-19, need for intensive care unit admission and mechanical ventilation, death, and therapeutic changes related to IMRD. Two outcomes—pulmonary and thromboembolic events in patients with both IMRD and SARS-CoV-2 infection—are of particular interest and will be monitored with close attention (clinical, laboratory, and function tests as well as imaging). Results: Recruitment opened in May 2020, with 1300 participants recruited from 43 sites as of November 2020. Patient recruitment will conclude by the end of December 2020, with follow-up occurring until April 2021. Data analysis is scheduled to start after all inclusion data have been collected, with an aim to publish a peer-reviewed paper in December 2020. Conclusions: We believe this study will provide clinically relevant data on the general impact of COVID-19 on patients with IMRD.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofJMIR research protocols. Toronto. Vol. 9, no. 12 (2020), e24357. 12 p.pt_BR
dc.rightsOpen Accessen
dc.subjectSARS-CoV-2pt_BR
dc.subjectProspective studyen
dc.subjectImmune-mediated rheumatic diseasesen
dc.subjectDoenças reumáticaspt_BR
dc.subjectRegistryen
dc.subjectInflamaçãopt_BR
dc.subjectDoença crônicapt_BR
dc.subjectBrazilen
dc.subjectInflammatoryen
dc.subjectCOVID-19pt_BR
dc.subjectChronic diseaseen
dc.subjectMortalidadept_BR
dc.subjectCohorten
dc.subjectMorbidadept_BR
dc.subjectImmunologyen
dc.subjectInfection rateen
dc.subjectMortalityen
dc.subjectMorbidityen
dc.titleA Brazilian cohort of patients with immuno-mediated chronic inflammatory diseases infected by SARS-CoV-2 (ReumaCoV-Brasil Registry) : protocol for a prospective, observational studypt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb001146479pt_BR
dc.type.originEstrangeiropt_BR


Files in this item

Thumbnail
   

This item is licensed under a Creative Commons License

Show simple item record